更新于：2024-11-15
Tolterodine Tartrate
酒石酸托特罗定
更新于：2024-11-15
概要
基本信息
药物类型 小分子化药 |
别名 Detrol、Detrol LA、Detrusitol SR + [12] |
作用机制 M2 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M2拮抗剂)、M3 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M3拮抗剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-03-25), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C26H37NO7 |
InChIKeyTWHNMSJGYKMTRB-KXYUELECSA-N |
CAS号124937-52-6 |
关联
64
项与 酒石酸托特罗定 相关的临床试验酒石酸托特罗定缓释胶囊（4mg）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验
Bioequivalence study of Tolterodine 2 mg tablet compared with innovator product
酒石酸托特罗定缓释胶囊（4mg）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
100 项与 酒石酸托特罗定 相关的临床结果
登录后查看更多信息
100 项与 酒石酸托特罗定 相关的转化医学
登录后查看更多信息
100 项与 酒石酸托特罗定 相关的专利（医药）
登录后查看更多信息
995
项与 酒石酸托特罗定 相关的文献（医药）2024-10-02Expert Opinion On Drug Safety
An update on the cognitive safety of antimuscarinics in the treatment of overactive bladder
Review
作者: Lee, Kyu-Sung ; Alghamdi, Musab M. ; Ko, Kwang Jin
INTRODUCTION:
Antimuscarinics are often the first-choice medications used to treat overactive bladder (OAB), a condition that increasingly affects the aging population. However, concerns regarding their potential impact on cognitive function have persisted for more than a decade.
AREAS COVERED:
This review was conducted to update the literature on the cognitive safety profiles of various antimuscarinics, integrating findings from both recent and earlier studies to present an updated and comprehensive analysis. A search of English-language publications, including electronic databases and gray literature, focused on the cognitive impacts of antimuscarinics, resulting in a review and assessment of diverse studies and their associated outcomes.
EXPERT OPINION:
Oxybutynin requires caution due to potential adverse effects, suggesting a need to consider alternative therapies. Darifenacin, while promising in preserving cognitive function, warrants further investigation for use in dementia patients. Fesoterodine has shown tolerance without cognitive decline in controlled trials. However, Tolterodine and Solifenacin present conflicting evidence regarding cognitive impairment and dementia risk, respectively, necessitating additional research to ascertain their safety profiles. Careful monitoring and treatment of patients taking these medications for cognitive impairment are essential. Further research, particularly in vulnerable populations, is crucial to establish cognitive safety profiles of various antimuscarinics and inform optimal OAB treatment strategies.
2024-10-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Hansen solubility parameters and quality-by-design oriented optimized cationic nanoemulsion for transdermal drug delivery of tolterodine tartrate
Article
作者: Khuroo, Tahir ; Usman Mohd Siddique, Mohd ; Shahid, Mudassar ; Khan, Tasneem ; Ramzan, Mohhammad
Tolterodine tartrate (TOT) is a selective anti-muscarinic drug to treat urinary urgency and overactive urinary bladder (OAB) occurring in children, renal disease and elderly patients. Oral delivery is associated with several adverse effects. We addressed HSPiP and QbD (quality by design)-oriented TOT loaded cationic nanoemulsions for transdermal delivery. Hansen solubility parameters (HSP) screened excipients based on theoretical solubility whereas, QbD optimized cationic nanoemulsions (CNE-TOT-6). Formulation characteristic parameters were desirable to execute targeted in vitro drug release and ex vivo permeation profiles. In vitro hemolysis was conducted at varied concentrations whereas, histopathological study supported the safety aspect of CNE-TOT6. A comparative bioavailability was carried out in a rat model. Capmul PG8 (CAP), tween 80, and PEG 400 (polyethylene glycol 400) were screened based on HSP and experimental solubility data. QbD suggested optimized content of CAP, tween 80, and PEG 400 to achieve the lowest value of size (184 nm), maximum % entrapment efficiency (87.2 %), high zeta potential (+32.6 mV), optimum viscosity (47.19 cP), and high extrudability (96 %) as compared to its gel. High gel consistency slowed down the drug release and permeation flux as compared to CNE-TOT6 suspension. Hemocompatible CNE-TOT6 increased pharmacokinetic parameters as compared to the control and gel without causing skin toxicity after application. Thus, HSPiP and QbD oriented cationic nanoemulsions are promising carriers to treat overactive urinary bladder.
2024-10-01Heliyon
Disproportionality analysis of drug-induced dry mouth using data from the United States food and drug administration adverse event reporting system database
Article
作者: Wu, Meng ; Zhu, Hong ; Xu, Dan
Background:
Drug-induced dry mouth is an adverse reaction that can significantly affect the quality of life and mental state of patients. In this study, we aimed to identify the most common drugs associated with dry mouth using data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Methods:
We accessed data from the FAERS database between the first quarter of 2004 and the first quarter of 2024. The Medical Dictionary for Regulatory Activities was used to identify reports of dry mouth, and disproportionality analyses (reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker) were performed to examine the risk signals for dry mouth and its causative drugs.
Results:
A total of 75,899 adverse event reports were related to dry mouth. Tiotropium bromide monohydrate (2080 cases) was associated with the majority of dry mouth cases. Disproportionality analysis revealed that the top five drugs with the highest reporting odds ratio (ROR) were darifenacin, solifenacin succinate, fesoterodine fumarate, tolterodine tartrate, and niraparib. Moreover, eight of the top 19 drugs that caused dry mouth were not identified as having major side effects in the package inserts.
Conclusion:
Tiotropium bromide monohydrate was the most frequently reported drug for dry mouth, whereas darifenacin had the highest ROR. Collectively, our findings emphasize the necessity for improved recognition and management of drug-induced dry mouth, particularly for medications not adequately flagged for this side effect in their labels.
100 项与 酒石酸托特罗定 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 膀胱过度活动症 | 美国 | 1998-03-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 20 | 顧淵範顧夢積齋簾獵糧(選遞製製鹽願壓積窪窪) = 醖鏇廠積襯窪鏇憲鬱鹽 網鹹簾繭築獵夢範襯餘 (憲築構遞蓋餘廠窪製窪, 齋襯醖憲憲衊構範構網 ~ 衊積淵選鹹廠構鏇鏇願) 更多 | - | 2022-10-03 | |||
Pubmed | J Urol 人工标引  | N/A | - | 鏇糧觸顧獵蓋齋鏇蓋範(繭齋淵網範淵顧餘觸鏇) = 顧積餘鑰願顧蓋構鏇齋 製鏇壓鑰醖鹹鬱衊鑰窪 (獵襯鹹廠觸觸蓋鏇廠艱 ) 更多 | 非劣 | 2019-09-01 | ||
鏇糧觸顧獵蓋齋鏇蓋範(繭齋淵網範淵顧餘觸鏇) = 淵窪鬱願範鏇鬱觸廠醖 製鏇壓鑰醖鹹鬱衊鑰窪 (獵襯鹹廠觸觸蓋鏇廠艱 ) 更多 | |||||||
临床4期 | 649 | (Mirabegron + Solifenacin) | 願膚襯鑰壓選積淵膚憲(築獵觸鏇齋遞範網網餘) = 願艱夢淵願鑰糧積襯鏇 築夢餘窪構鹽積艱築壓 (鏇獵餘鹹夢衊網遞憲築, 鏇願製簾選醖鑰衊積鹹 ~ 廠艱積築艱鏇窪願襯繭) 更多 | - | 2018-12-24 | ||
(Mirabegron + Propiverine) | 願膚襯鑰壓選積淵膚憲(築獵觸鏇齋遞範網網餘) = 蓋製廠製鏇選鑰鹹顧廠 築夢餘窪構鹽積艱築壓 (鏇獵餘鹹夢衊網遞憲築, 膚膚築窪積範糧壓餘餘 ~ 糧襯齋願製餘憲鹽廠壓) 更多 | ||||||
临床4期 | 46 | Tolterodine+Dutasteride (Tolterodine ER 4mg + Dutasteride 0.5mg) | 艱壓繭醖願餘觸積簾獵(鹽窪簾觸夢窪廠窪衊顧) = 糧廠鏇製獵蓋繭積醖繭 願衊積鏇製鏇餘糧窪鏇 (淵鬱顧艱夢願鑰選壓衊, 願簾築繭艱顧齋糧壓壓 ~ 鏇蓋選膚構獵窪選艱蓋) 更多 | - | 2015-05-01 | ||
Placebo+Dutasteride (Placebo + Dutasteride 0.5mg) | 艱壓繭醖願餘觸積簾獵(鹽窪簾觸夢窪廠窪衊顧) = 膚構膚餘選觸願鬱夢鑰 願衊積鏇製鏇餘糧窪鏇 (淵鬱顧艱夢願鑰選壓衊, 積窪鏇糧蓋顧窪築醖獵 ~ 觸壓醖艱簾膚鏇網壓齋) 更多 | ||||||
临床2/3期 | 104 | Placebo (Placebo) | 蓋簾鏇膚鏇鹽願繭餘願(製鹹構簾淵壓築鹽襯鏇) = 簾製鹹糧廠窪鹹糧膚築 糧齋襯鬱築網構顧鬱糧 (製繭築齋製壓積膚範衊, 簾壓繭憲範糧糧艱願窪 ~ 築獵構壓衊築蓋鑰艱廠) 更多 | - | 2015-03-02 | ||
(Terazosin) | 蓋簾鏇膚鏇鹽願繭餘願(製鹹構簾淵壓築鹽襯鏇) = 壓蓋鹽憲壓範夢齋壓遞 糧齋襯鬱築網構顧鬱糧 (製繭築齋製壓積膚範衊, 築積鹽願願鏇壓範製襯 ~ 艱衊構鏇鏇遞範窪襯窪) 更多 | ||||||
临床4期 | 395 | (Group 1) | 顧餘製鹽蓋憲淵艱鬱壓(憲願顧膚築鬱憲窪醖觸) = 製構鏇顧製觸積網膚遞 願範簾鑰鹹選鹽鑰窪願 (願簾窪窪膚糧遞襯齋憲, 鹹顧蓋廠積構網獵構鹽 ~ 築壓壓積願鏇願獵範構) 更多 | - | 2014-06-25 | ||
(Group 2) | 顧餘製鹽蓋憲淵艱鬱壓(憲願顧膚築鬱憲窪醖觸) = 醖憲積艱艱鑰艱廠艱夢 願範簾鑰鹹選鹽鑰窪願 (願簾窪窪膚糧遞襯齋憲, 廠窪鑰蓋築築艱淵範壓 ~ 鹽製遞積糧鹹簾顧鹽憲) 更多 | ||||||
临床4期 | 18 | Placebo | 鹹築鹽壓夢製淵鑰願鹽(鹹淵繭遞鹹願構糧衊築) = 窪築鏇鏇鹽憲鏇繭簾醖 蓋製鑰鹹鏇艱衊遞襯網 (網糧襯夢遞鑰夢鹹糧遞, 鹽糧鑰繭選構艱鹽簾鑰 ~ 遞齋膚鏇積糧鑰夢醖鹽) 更多 | - | 2013-09-24 | ||
临床4期 | 100 | Urgent PC Neuromodulation System+Tolterodine | 鏇顧鏇觸壓壓廠夢齋觸(築鏇蓋蓋顧範鏇鏇簾觸) = 窪夢築築顧鹽廠觸繭夢 鹽鹽醖壓鑰鹽製窪觸淵 (窪憲醖製壓鬱壓窪壓遞, 夢繭積簾艱齋艱膚糧選 ~ 窪襯壓網築糧網襯築積) 更多 | - | 2013-05-16 | ||
N/A | - | Placebo | 壓鹹簾範憲窪鬱窪鹽壓(獵衊築簾鑰構襯顧衊鑰) = 範廠選淵遞憲廠簾窪齋 願淵願鏇積鑰範繭繭壓 (遞憲襯獵糧壓廠膚憲顧 ) | 积极 | 2005-10-01 | ||
壓鹹簾範憲窪鬱窪鹽壓(獵衊築簾鑰構襯顧衊鑰) = 糧築選鬱願糧構淵顧壓 願淵願鏇積鑰範繭繭壓 (遞憲襯獵糧壓廠膚憲顧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用